edoc

Items where Author is "Zaman, K."

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Date | Item Type | Refereed
Jump to: 2015 | 2011 | 2008
Number of items: 5.

2015

Zaman, K. and Winterhalder, R. and Mamot, C. and Hasler-Strub, U. and Rochlitz, C. and Mueller, A. and Berset, C. and Wiliders, H. and Perey, L. and Rudolf, C. B. and Hawle, H. and Rondeau, S. and Neven, P.. (2015) Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. European Journal of Cancer, 51 (10). pp. 1212-1220.

2011

Rochlitz, C. and Ruhstaller, T. and Lerch, S. and Spirig, C. and Huober, J. and Suter, T. and Buhlmann, M. and Fehr, M. and Schonenberger, A. and von Moos, R. and Winterhalder, R. and Rauch, D. and Muller, A. and Mannhart-Harms, M. and Herrmann, R. and Cliffe, B. and Mayer, M. and Zaman, K.. (2011) Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer : a multicenter, single-arm phase II trial (SAKK 24/06). Annals of oncology, Vol. 22, H. 1. pp. 80-85.

Koeberle, D. and Ruhstaller, T. and Jost, L. and Pagani, O. and Zaman, K. and von Moos, R. and Oehlschlegel, C. and Crowe, S. and Pilop, C. and Thuerlimann, B. and Swiss Grp Clinical Canc Res Sakk, . (2011) Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer : a proof-of-concept trial (SAKK 23/03). Endocrine related cancer, Vol. 18, H. 2. pp. 257-264.

Laurent, J. and Hull, E. F. and Touvrey, C. and Kuonen, F. and Lan, Q. and Lorusso, G. and Doucey, M. A. and Ciarloni, L. and Imaizumi, N. and Alghisi, G. C. and Fagiani, E. and Zaman, K. and Stupp, R. and Shibuya, M. and Delaloye, J. F. and Christofori, G. and Ruegg, C.. (2011) Proangiogenic factor PlGF programs CD11b(+) myelomonocytes in breast cancer during differentiation of their hematopoietic progenitors. Cancer research, Vol. 71,11. pp. 3781-3791.

2008

Degen, M. and Brellier, F. and Schenk, S. and Driscoll, R. and Zaman, K. and Stupp, R. and Tornillo, L. and Terracciano, L. and Chiquet-Ehrismann, R. and Rüegg, C. and Seelentag, W.. (2008) Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients. International journal of cancer, Vol. 122, H. 11. pp. 2454-2461.

This list was generated on Thu Mar 28 17:49:22 2024 CET.